Ban on Mercury-Containing Fluorescent Light Bulbs

Maine DEP announced enforcement of legislation enacted in 2023 banning the sale and distribution of mercury-containing fluorescent light bulbs effective January 1, 2026. The ban affects retailers and consumers throughout Maine and covers all types of mercury-containing fluorescent bulbs including linear, compact, black light, high-intensity discharge, ultraviolet, and neon variants. The legislation aims to reduce mercury pollution and protect public health and the environment.

10 Maine Wetland Projects Awarded $4.6M Funding

The Maine Department of Environmental Protection announced that the Maine Natural Resource Conservation Program awarded $4,633,343 to 10 wetland restoration and conservation projects across the state. Funding recipients include public agencies, municipalities, Tribes, and nonprofit organizations implementing projects such as salt marsh restoration, eelgrass restoration, dam removal, and wetland reconnection. The announcement covers projects in York, Yarmouth, Buckfield, Waldoboro, Aroostook County, and Acadia National Park.

Maine DEP Solid Waste Diversion Grant Program 2026

Maine DEP announced $165,000 in solid waste diversion grants for 2026, with awards ranging from $1,000 to $25,000. The program targets municipalities, regional associations, and Maine businesses proposing organic waste diversion, composting, source reduction, and upcycling initiatives. Priority funding goes to municipal and regional applicants.

Maine DEP Releases Statewide Waste Characterization Study Findings

Maine Department of Environmental Protection announced findings from a comprehensive statewide waste characterization study funded by the EPA's Solid Waste Infrastructure for Recycling grant program. The study, conducted by MSW Consultants, provides detailed data on Maine's waste stream composition through facility gate surveys, hand sorting, and seasonal sampling of municipal solid waste and construction debris.

Clinical Trial Registration NCT07511621

The National Library of Medicine registered clinical trial NCT07511621 on ClinicalTrials.gov. This represents a new trial entry in the federal clinical trial registry database. No compliance deadlines or penalties are associated with this registration.

OHSU Y-90 radioembolization with immunotherapy liver cancer trial

National Library of Medicine registered a new clinical trial (NCT07511504) conducted by Oregon Health & Science University investigating Y-90 radioembolization combined with immunotherapy for liver cancer treatment. The trial is listed on ClinicalTrials.gov as a participant enrollment opportunity.

TQD3524 Phase 1 trial targets carbapenem-resistant bacterial pneumonia

The National Library of Medicine's ClinicalTrials.gov registered a new Phase 1 study (NCT07512596) evaluating TQD3524 for treatment of carbapenem-resistant bacterial pneumonia. The trial involves drug manufacturers and clinical investigators conducting first-in-human studies.

First-in-human UX016 study for GNE Myopathy, Ultragenyx Pharmaceutical

ClinicalTrials.gov registered a first-in-human Phase 1/2 study (NCT07511556) evaluating UX016 for GNE Myopathy, sponsored by Ultragenyx Pharmaceutical. The study represents an early-stage clinical trial for a rare hereditary muscle disease. No compliance deadlines or penalties are associated with this registration notice.

Mayo Clinic methotrexate monitoring trial, rheumatic diseases

The National Library of Medicine registered a new clinical trial (NCT07512401) on ClinicalTrials.gov. The study, sponsored by Mayo Clinic, will investigate methotrexate monitoring practices in patients with rheumatic diseases. The trial is currently recruiting participants at Mayo Clinic locations in Arizona and Minnesota.

CAR-NK Cell Therapy Trial for HER2+ Breast Cancer

ClinicalTrials.gov registered a Phase I/II clinical trial (NCT07510802) evaluating CAR-NK cell therapy for HER2+ breast cancer. The trial is sponsored by a Beijing-based biotechnology company. This registry entry provides public disclosure of ongoing research but does not establish new regulatory obligations.